Transcriptional and phenotypic signatures of PBMCs in patients with AML exhibiting robust vs weak CRT exposure on blasts. (A) Nanostring-assisted quantification of NK cell–related mRNAs in PBMCs from 6 CRT^Hi vs 6 CRT^Lo patients with AML at recovery of normal hematopoiesis. The Mann-Whitney test was employed to assess intergroup variations. (B) qRT-PCR–assisted quantification of KIR2DL1, KIR2DL2, and KIR2DL3 (cumulatively as CD158 family members), KLRF1, KLRC2, and NCR1 in PBMCs from 20 CRT^Hi vs 20 CRT^Lo patients with AML at recovery of normal hematopoiesis. Box plots: lower quartile, median, upper quartile; whiskers, minimum value, maximum value. (C-D) Percentage of circulating CD33⁻CD3⁻CD56⁺ NK cells (C), CD45⁺CD3⁺CD4⁺ T cells, and CD45⁺CD3⁺CD8⁺ T cells in 13 CRT^Hi vs 13 CRT^Lo patients with AML before induction chemotherapy (Prior, D) and at reestablishment of normal hematopoiesis (Recovery, C-D). Box plots: lower quartile, median, upper quartile; whiskers, minimum value, maximum value. (E) Percentage of IFN-γ–producing cells among CD45⁺CD3⁺CD4⁺ T cells and CD45⁺CD3⁺CD8⁺ T cells from 13 CRT^Hi vs 13 CRT^Lo patients with AML before induction chemotherapy (Prior) and at reestablishment of normal hematopoiesis (Recovery). Box plots: lower quartile, median, upper quartile; whiskers, minimum value, maximum value. (F) Distribution of circulating CD45⁺CD3⁺CD8⁺ T cells and CD45⁺CD3⁺CD4⁺ T cells in 20 CRT^Hi vs 20 CRT^Lo patients with AML before (Prior) and after (Post) induction chemotherapy. Mean percentage values are depicted as pie charts. Central memory: CD45RA⁻CD45RO⁺CCR7⁺CD62L⁺; effector memory: CD45RA⁻CD45RO⁺CCR7⁻CD62L⁻; naive: CD45RA⁺CD45RO⁻CCR7⁺CD62L⁺; terminally differentiated: CD45RA⁺CD45RO⁻CCR7⁻CD62L⁻.